Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Easton Capital Fund Structure Fits The Times

This article was originally published in Start Up

Executive Summary

Easton capital has secured roughly $20 million for a “special situations” fund of unusual design. The new fund is a five-year commitment between general partners and limited partners with the potential for three one-year extensions. Limited partners estimate the average life of a typical venture fund to be roughly 15 years. Easton Capital’s fund will be concluded in half the time.

You may also be interested in...



Glaukos Holds Lead In Microinvasive Glaucoma Surgery

Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.

Finding The Fit For Ophthalmology In The New Pfizer

The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.

New Enterprise Flies Higher

New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel